Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Eli Lilly and Company

LLY
Current price
745.91 USD +7.83 USD (+1.06%)
Last closed 782.06 USD
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NYSE
Capitalization 717 353 320 448 USD
Yield for 12 month +126.67 %
1Y
3Y
5Y
10Y
15Y
LLY
21.11.2021 - 28.11.2021

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; Foghorn Therapeutics Inc., and PRISM BioLab Co.,Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Address: Lilly Corporate Center, Indianapolis, IN, United States, 46285

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

760.37 USD

P/E ratio

136.8949

Dividend Yield

0.69 %

Current Year

+32 072 500 000 USD

Last Year

+28 541 400 000 USD

Current Quarter

+9 498 600 000 USD

Last Quarter

+8 312 100 000 USD

Current Year

+25 230 200 000 USD

Last Year

+21 911 600 000 USD

Current Quarter

+7 638 500 000 USD

Last Quarter

+6 504 700 000 USD

Key Figures LLY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 11 844 866 048 USD
Operating Margin TTM 32.91 %
PE Ratio 136.8949
Return On Assets TTM 11.63 %
PEG Ratio 1.806
Return On Equity TTM 47.46 %
Wall Street Target Price 760.37 USD
Revenue TTM 34 124 099 584 USD
Book Value 12.48 USD
Revenue Per Share TTM 37.78 USD
Dividend Share 4.52 USD
Quarterly Revenue Growth YOY 28.1 %
Dividend Yield 0.69 %
Gross Profit TTM 21 911 600 000 USD
Earnings Share 5.52 USD
Diluted Eps TTM 5.52 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY 13.1 %
Profit Margin 15.36 %

Dividend Analytics LLY

Dividend growth over 5 years

151 %

Continuous growth

9 years

Payout Ratio 5 years average

62 %

Dividend History LLY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 5.2
Ex Dividend Date 14.02.2024
Forward Annual Dividend Yield 0.69 %
Last Split Factor 2:1
Payout Ratio 74.21 %
Last Split Date 16.10.1997
Dividend Date 08.03.2024

Stock Valuation LLY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 136.8949
Forward PE 59.8802
Enterprise Value Revenue 21.5398
Price Sales TTM 21.0219
Enterprise Value EBITDA 71.1864
Price Book MRQ 63.933

Financials LLY

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators LLY

For 52 weeks

306.63 USD 794.47 USD
50 Day MA 636.18 USD
Shares Short Prior Month 5 093 399
200 Day MA 546.36 USD
Short Ratio 1.49
Shares Short 4 412 216
Short Percent 0.56 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

402.79 USD Microsoft Corporation -0.45 (-0.11%)
Detailed analytics

ETF funds


S

SX7EEX

11.59 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2031.07 USD Gold +9.2 (+0.46%)
Detailed analytics